Phase I trial of recombinant interferon gamma in cancer patients

S. Vadhan-Raj, A. Al-Katib, R. Bhalla, L. Pelus, C. F. Nathan, S. A. Sherwin, H. F. Oettgen, S. E. Krown

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Interferon gamma (IFN-γ) is a lymphokine with potent in vitro effects on cell growth and immune function. We have investigated the effects of rIFN-γ (sp act ~ 2 x 107 U/mg, purity > 99%) in 16 evaluable patients with advanced malignancy in a phase I trial. Patients were treated with six-hour intravenous (IV) infusions daily, five days a week for 2 weeks. After a 2-week rest period, the IV treatment cycle was repeated. Responders were maintained on repeated IV treatment cycles or daily intramuscular (IM) injections. Patients were entered at fixed dose levels of 0.1, 0.5, or 1.0 mg/m2/d. The maximum safely tolerated dose was 0.5 mg/m2. The most common side effects were constitutional symptoms, including fever, chills, fatigue, and myalgias. Reversible and transient increases in hepatic transaminase and decrease in granulocyte counts were seen. Treatment was associated with a dose-dependent increase in serum levels of β2 microglobulin. Partial responses (PRs) were observed in one patient with Hodgkin's disease and one patient with chronic lymphocytic leukemia. Fairly constant levels of serum IFN were found at four and six hours during infusion, followed by a rapid decline within one to two hours. We conclude that rIFN-γ can be safely administered by a six-hour IV infusion and that it can induce in vivo some of the biologic effects reported in in vitro studies.

Original languageEnglish (US)
Pages (from-to)137-146
Number of pages10
JournalJournal of Clinical Oncology
Volume4
Issue number2
DOIs
StatePublished - Jan 1 1986

Fingerprint

Interferon-gamma
Neoplasms
Intravenous Infusions
Chills
Maximum Tolerated Dose
Lymphokines
Myalgia
Intramuscular Injections
B-Cell Chronic Lymphocytic Leukemia
Transaminases
Serum
Hodgkin Disease
Granulocytes
Fatigue
Fever
Therapeutics
Liver
Growth
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vadhan-Raj, S., Al-Katib, A., Bhalla, R., Pelus, L., Nathan, C. F., Sherwin, S. A., ... Krown, S. E. (1986). Phase I trial of recombinant interferon gamma in cancer patients. Journal of Clinical Oncology, 4(2), 137-146. https://doi.org/10.1200/JCO.1986.4.2.137

Phase I trial of recombinant interferon gamma in cancer patients. / Vadhan-Raj, S.; Al-Katib, A.; Bhalla, R.; Pelus, L.; Nathan, C. F.; Sherwin, S. A.; Oettgen, H. F.; Krown, S. E.

In: Journal of Clinical Oncology, Vol. 4, No. 2, 01.01.1986, p. 137-146.

Research output: Contribution to journalArticle

Vadhan-Raj, S, Al-Katib, A, Bhalla, R, Pelus, L, Nathan, CF, Sherwin, SA, Oettgen, HF & Krown, SE 1986, 'Phase I trial of recombinant interferon gamma in cancer patients', Journal of Clinical Oncology, vol. 4, no. 2, pp. 137-146. https://doi.org/10.1200/JCO.1986.4.2.137
Vadhan-Raj S, Al-Katib A, Bhalla R, Pelus L, Nathan CF, Sherwin SA et al. Phase I trial of recombinant interferon gamma in cancer patients. Journal of Clinical Oncology. 1986 Jan 1;4(2):137-146. https://doi.org/10.1200/JCO.1986.4.2.137
Vadhan-Raj, S. ; Al-Katib, A. ; Bhalla, R. ; Pelus, L. ; Nathan, C. F. ; Sherwin, S. A. ; Oettgen, H. F. ; Krown, S. E. / Phase I trial of recombinant interferon gamma in cancer patients. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 2. pp. 137-146.
@article{363ba66f6d574a80bf8cde2b756e022d,
title = "Phase I trial of recombinant interferon gamma in cancer patients",
abstract = "Interferon gamma (IFN-γ) is a lymphokine with potent in vitro effects on cell growth and immune function. We have investigated the effects of rIFN-γ (sp act ~ 2 x 107 U/mg, purity > 99{\%}) in 16 evaluable patients with advanced malignancy in a phase I trial. Patients were treated with six-hour intravenous (IV) infusions daily, five days a week for 2 weeks. After a 2-week rest period, the IV treatment cycle was repeated. Responders were maintained on repeated IV treatment cycles or daily intramuscular (IM) injections. Patients were entered at fixed dose levels of 0.1, 0.5, or 1.0 mg/m2/d. The maximum safely tolerated dose was 0.5 mg/m2. The most common side effects were constitutional symptoms, including fever, chills, fatigue, and myalgias. Reversible and transient increases in hepatic transaminase and decrease in granulocyte counts were seen. Treatment was associated with a dose-dependent increase in serum levels of β2 microglobulin. Partial responses (PRs) were observed in one patient with Hodgkin's disease and one patient with chronic lymphocytic leukemia. Fairly constant levels of serum IFN were found at four and six hours during infusion, followed by a rapid decline within one to two hours. We conclude that rIFN-γ can be safely administered by a six-hour IV infusion and that it can induce in vivo some of the biologic effects reported in in vitro studies.",
author = "S. Vadhan-Raj and A. Al-Katib and R. Bhalla and L. Pelus and Nathan, {C. F.} and Sherwin, {S. A.} and Oettgen, {H. F.} and Krown, {S. E.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1200/JCO.1986.4.2.137",
language = "English (US)",
volume = "4",
pages = "137--146",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase I trial of recombinant interferon gamma in cancer patients

AU - Vadhan-Raj, S.

AU - Al-Katib, A.

AU - Bhalla, R.

AU - Pelus, L.

AU - Nathan, C. F.

AU - Sherwin, S. A.

AU - Oettgen, H. F.

AU - Krown, S. E.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Interferon gamma (IFN-γ) is a lymphokine with potent in vitro effects on cell growth and immune function. We have investigated the effects of rIFN-γ (sp act ~ 2 x 107 U/mg, purity > 99%) in 16 evaluable patients with advanced malignancy in a phase I trial. Patients were treated with six-hour intravenous (IV) infusions daily, five days a week for 2 weeks. After a 2-week rest period, the IV treatment cycle was repeated. Responders were maintained on repeated IV treatment cycles or daily intramuscular (IM) injections. Patients were entered at fixed dose levels of 0.1, 0.5, or 1.0 mg/m2/d. The maximum safely tolerated dose was 0.5 mg/m2. The most common side effects were constitutional symptoms, including fever, chills, fatigue, and myalgias. Reversible and transient increases in hepatic transaminase and decrease in granulocyte counts were seen. Treatment was associated with a dose-dependent increase in serum levels of β2 microglobulin. Partial responses (PRs) were observed in one patient with Hodgkin's disease and one patient with chronic lymphocytic leukemia. Fairly constant levels of serum IFN were found at four and six hours during infusion, followed by a rapid decline within one to two hours. We conclude that rIFN-γ can be safely administered by a six-hour IV infusion and that it can induce in vivo some of the biologic effects reported in in vitro studies.

AB - Interferon gamma (IFN-γ) is a lymphokine with potent in vitro effects on cell growth and immune function. We have investigated the effects of rIFN-γ (sp act ~ 2 x 107 U/mg, purity > 99%) in 16 evaluable patients with advanced malignancy in a phase I trial. Patients were treated with six-hour intravenous (IV) infusions daily, five days a week for 2 weeks. After a 2-week rest period, the IV treatment cycle was repeated. Responders were maintained on repeated IV treatment cycles or daily intramuscular (IM) injections. Patients were entered at fixed dose levels of 0.1, 0.5, or 1.0 mg/m2/d. The maximum safely tolerated dose was 0.5 mg/m2. The most common side effects were constitutional symptoms, including fever, chills, fatigue, and myalgias. Reversible and transient increases in hepatic transaminase and decrease in granulocyte counts were seen. Treatment was associated with a dose-dependent increase in serum levels of β2 microglobulin. Partial responses (PRs) were observed in one patient with Hodgkin's disease and one patient with chronic lymphocytic leukemia. Fairly constant levels of serum IFN were found at four and six hours during infusion, followed by a rapid decline within one to two hours. We conclude that rIFN-γ can be safely administered by a six-hour IV infusion and that it can induce in vivo some of the biologic effects reported in in vitro studies.

UR - http://www.scopus.com/inward/record.url?scp=0022600846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022600846&partnerID=8YFLogxK

U2 - 10.1200/JCO.1986.4.2.137

DO - 10.1200/JCO.1986.4.2.137

M3 - Article

C2 - 3080551

AN - SCOPUS:0022600846

VL - 4

SP - 137

EP - 146

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -